IKBKB and hyperlipidemia: Significantly reduced liver steatosis and inflammation in both models:(a) Liver of ob/ob+ group had reduced levels of phosphorylated Ikkβ and NFκB compared to ob/ob+ vehicle mice, at 80% and 20%, respectively, p < 0.05. But it did not affect TNF-α expression (b) Treatment induced a substantial reduction in TNF-α, levels of F4/80 mRNA, and reverted enhanced IL-1β and induced enhancement of IL-10 and arginase-1 expression.Subacute oral toxicity was >2000 mg/kg. GlucoMedix® was a safe and effective treatment for hyperglycemia, hyperlipidemia, and hypertension